Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
2024年4月12日 - 5:30AM
ビジネスワイヤ(英語)
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the
Company will provide a corporate update and report financial
results for the first quarter ended March 31, 2024, on May 2, 2024.
The Company will host a conference call at 1:30 p.m. Pacific Time /
4:30 p.m. Eastern Time on May 2, 2024.
The corporate update and financial results will be provided via
a press release after market close and will be accessible under
Press Releases in the Investors section of the Vir website at
www.vir.bio. Participants may access the conference call via
webcast on the Events & Presentations page of Vir’s website at
https://investors.vir.bio/events-presentations or listen in by
dialing the U.S. toll free number (888) 800-8770 or international
+1 (646) 307-1953, Conference ID: 756877. A recorded version of the
call will be available on the website approximately two hours after
the completion of the event and will be archived there for 30
days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on
powering the immune system to transform lives by treating and
preventing infectious diseases and other serious conditions,
including viral-associated diseases. Vir has assembled two
technology platforms that are designed to modulate the immune
system by exploiting critical observations of natural immune
processes. Its current clinical development pipeline consists of
product candidates targeting hepatitis delta and hepatitis B
viruses and human immunodeficiency virus. Vir has several
preclinical candidates in its pipeline, including those targeting
influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts
information that may be important to investors on its website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240411706041/en/
Media Carly Scaduto Senior Director, External
Communications cscaduto@vir.bio +1 314-368-5189
Investors Richard Lepke Senior Director, Investor
Relations rlepke@vir.bio +1 978-973-9986
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 8 2024 まで 9 2024
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 9 2023 まで 9 2024